Thrombomodulin alfa - Asahi Kasei Pharma

Drug Profile

Thrombomodulin alfa - Asahi Kasei Pharma

Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma; Recombinant thrombomodulin alfa - Asahi Kasei Pharma; Recombinant thrombomodulin alpha - Asahi Kasei Pharma; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma; Thrombomodulin alpha - Asahi Kasei Pharma; TMD-123

Latest Information Update: 07 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asahi Kasei; Asahi Kasei Pharma Corp
  • Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp
  • Class Anti-inflammatories; Anticoagulants; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Disseminated intravascular coagulation
  • Phase III Idiopathic pulmonary fibrosis
  • No development reported Deep vein thrombosis

Most Recent Events

  • 02 Aug 2018 Preliminary efficacy and pharmacodynamics data from the phase III SCARLET trial in Disseminated intravascular coagulation released by Asahi Kasei Pharma America Corp
  • 07 May 2018 Asahi Kasei Pharma America Corporation plans the Scarlet2 phase III trial for Sepsis and Coagulation blood disorder in July 2018 , (NCT03517501)
  • 01 Feb 2018 Asahi Kasei Pharma Corporation completes a phase I trial for prevention of treatment-related symptoms in postoperative Colon Cancer in Japan (NCT02792842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top